Stocks Health care PTPI
OTC · Health carePetros Pharmaceuticals, Inc. (PTPI)
It posted a net loss of $3.2M. At June 30, 2026 it held $3.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Watch PTPI in 60 secondsWhat Petros Pharmaceuticals, Inc. does
Petros Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker PTPI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | $1.9M | -$1.56 | n/a |
| 2024 | $5.1M | -$14.3M | -$83.47 | -$2.6M |
| 2023 | $5.8M | -$8.2M | -$158.69 | n/a |
| 2022 | $6M | -$20M | -$241.91 | n/a |
| 2021 | $7.8M | -$9M | -$206.18 | n/a |
| 2021 | $9.6M | -$20.6M | -$956.36 | -$15.3M |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Petros Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026
- June 18, 2026
- June 5, 2026
- May 13, 2026
- April 15, 2026
- March 31, 2026Late annual report notice NT 10-K
- February 17, 2026Passive stake changed SCHEDULE 13G/A
- January 2, 2026
- November 20, 2025Delisting notice 25-NSE
- November 13, 2025
Insider trades
What the people running Petros Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 5, 2026 | Walker Wayne RemellDirector | Received as pay | 375,000 | - |
| June 5, 2026 | Silverman JoshuaDirector | Received as pay | 4,375,000 | - |
| June 5, 2026 | Bernstein BruceDirector | Received as pay | 1,875,000 | - |
| June 5, 2026 | Boctor FadySee Remarks | Received as pay | 375,000 | - |
| January 2, 2026 | Boctor FadySee Remarks | Received as pay | 500,000 | - |
| January 2, 2026 | Bernstein BruceDirector | Received as pay | 1,875,000 | - |
| January 2, 2026 | Walker Wayne RemellDirector | Received as pay | 500,000 | - |
| January 2, 2026 | Silverman JoshuaDirector | Received as pay | 4,375,000 | - |
Who owns PTPI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Richard Abbe13G, passive with 2 related filers | 9.99% | February 17, 2026 |
Largest institutional holders
Insiders
4 insiders reported holding 14,329,103 shares in total, about $57.3K at the last price.
| Holder | Shares |
|---|---|
| Silverman JoshuaDirector | 8,790,450 |
| Bernstein BruceDirector | 3,762,334 |
| Boctor FadySee Remarks | 894,986 |
| Walker Wayne RemellDirector | 881,333 |
Questions about PTPI
What does Petros Pharmaceuticals, Inc. do?
Petros Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker PTPI.
Is Petros Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $3.2M.
When did Petros Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026.
Similar companies
Compare PTPI with
Follow PTPI
Get an email when Petros Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow PTPI: get an email when it filesWhere the numbers come from
Financial figures are the values Petros Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.